A Bris­tol My­ers-backed biotech wants to treat heart dis­ease with non-cod­ing RNAs. It's one step clos­er to proof-of-con­cept

Is it pos­si­ble to use strands of non-cod­ing RNA, a bur­geon­ing ther­a­peu­tic area that re­searchers now be­lieve plays an im­por­tant part in how sim­i­lar genes are ex­pressed in dif­fer­ent tis­sues, to treat heart dis­ease? For Car­dior Ther­a­peu­tics, that’s the $76 mil­lion ques­tion.

The Hanover, Ger­many-based biotech com­plet­ed its Se­ries B round Wednes­day morn­ing with the promise of ad­vanc­ing its lead ncR­NA can­di­date in­to the next round of clin­i­cal tri­als. Hav­ing re­turned pos­i­tive Phase Ib re­sults last No­vem­ber, the pro­gram is now primed for a Phase II study in post-heart at­tack pa­tients suf­fer­ing from heart fail­ure, CEO Clau­dia Ul­brich told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER